Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Silexion Therapeutics ( (SLXN) ) is now available.
On December 16, 2025, Silexion Therapeutics announced the submission of a Phase 2/3 clinical trial application in Israel for their siRNA therapy, SIL204, targeting locally advanced pancreatic cancer. This regulatory milestone follows successful preclinical studies and positive feedback from German authorities, positioning Silexion to initiate trials in Q2 2026, with further filings planned for Germany and the EU in Q1 2026 and potential U.S. expansion thereafter.
The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA-based therapies for oncology. The company is dedicated to creating innovative treatments for solid tumor cancers with mutated KRAS oncogenes, which are common oncogenic drivers in human cancers.
Average Trading Volume: 176,761
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.79M
See more insights into SLXN stock on TipRanks’ Stock Analysis page.